EREyvind Rødahl

Eyvind Rødahl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eyvind Rødahl has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Loss of ATRAID in Late-Onset, Non-Syndromic Retinitis Pigmentosa

    by Roya Mehrasa, Ragnhild Wivestad Jansson, Hanah Kurosawa, Nita Singh, Per Morten Knappskog, Cecilie Bredrup, Lauren Surface, Ove Bruland, Eyvind Rødahl

    To identify and characterize a novel gene variant associated with late-onset, non-syndromic retinitis pigmentosa (RP). Ophthalmological examination included Goldmann perimetry, optical coherence tomography, fundus autofluorescence and full-field electroretinography. Gene variants were identified using whole exome sequencing. Expression of ATRAID in fibroblasts was studied using immunoblot analysis and quantitative PCR. Lysosomes were identified in ATRAID-/- and SLC37A3-/- cells using immunofluorescence analysis. Uptake of fluorescent dextran was measured using immunofluorescence analysis and flow cytometry. We first examined two siblings whose parents were second cousins. Ophthalmological examination revealed symmetrical midperipheral chorioretinal atrophy with bone spicules and vessel attenuation and a corresponding rod-cone dysfunction on full-field electroretinography consistent with RP. Whole exome sequencing identified a novel homozygous variant in the ATRAID gene (NM_001170795, c.120dup, p.Ser41Glufs*13) within a 12.45 Mb region of homozygosity, predicted to result in a premature stop codon. Immunoblot analysis confirmed protein absence, indicating a loss of function variant. Further analysis of individuals with similar clinical features identified this variant in a homozygous state in four additional affected individuals in three non-consanguineous families. ATRAID has been shown to interact with SLC37A3 in lysosomes. Recently, loss of SLC37A3 has been associated with non-syndromic RP with features resembling those seen in loss of ATRAID. Increased numbers of lysosomes and accumulation of fluorescein-labelled dextran were observed both in ATRAID-/- and SLC37A3-/- cells. We propose that biallelic loss of ATRAID causes RP through the disruption of ATRAID and SLC37A3 interaction resulting in impaired endocytic trafficking and lysosomal function.

  • Open Access

    Outcomes of malignant orbital tumors: a 22-year Norwegian single-center series

    by Bendik Alvheim Sundfjord, Julie Selvik Bentzon, Signe Johnsen Landa, Svein Arthur Jensen, Dorota Goplen, Jon Espen Dale, Stein Lybak, Hans Olav Ueland, Eyvind Rødahl

    Purpose: To evaluate outcome data for patients with malignant orbital tumors treated at Haukeland University Hospital over a 22 year period and compare them with existing literature. Methods: Patients were identified by searching for relevant codes in the Hospital's database. Medical records from patients with malignant orbital tumors treated from 1999 to 2020 were retrieved. Clinical features, management, and outcome was recorded. Incidence was estimated from yearly population data provided by Statistics Norway. Results: We included 76 patients, 41 (54%) females and 35 (46%) males corresponding to a yearly incidence in Western Norway of 0.30 per 100 000 inhabitants. Median age at time of diagnosis was 64 years (3-97 years). Secondary invading tumors were most frequently seen (46%), followed by lymphoproliferative (24%), metastatic (16%) and primary orbital tumors (14%). Biopsy and histopathologic confirmation were obtained in 73 out of 76 patients (96%). Of 40 different histological subgroups, squamous cell carcinoma from paranasal sinuses was the most common (16%). A total of 42 patients (55%) had their tumor surgically removed, of which 23 patients (55%) underwent exenteration. Local radiotherapy was administrated to 55 (72%) patients and 29 (38%) patients received chemotherapy. One or more local/regional relapses or distant metastases were seen in 32 (42%) patients. Overall disease specific 5-year survival was 59%, with significant differences between subgroups; lymphoproliferative diseases 82%, primary orbital tumors 80%, secondary invading tumors 46%, and orbital metastases 39%. Conclusion: The spectrum of malignant orbital tumors, treatment modalities, and survival rates aligned closely with international literature. While our findings demonstrate that high-quality care is feasible at a low-volume center, further studies on the volume-outcome relationship in orbital oncology is warranted.

  • Open Access

    Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis

    by Christopher Elnan Kvistad, Torbjørn Kråkenes, Trygve Holmøy, Live Egeland Eidem, Linn Steffensen, Kristin Wesnes, Markus Rojewski, Tom Eichele, Stig Wergeland, Sonia Gavasso, et al.

    Background and ObjectivesThere is an unmet need for neuroregenerative therapies in multiple sclerosis (MS). Mesenchymal stem cells (MSCs) have shown immunomodulatory and regenerative effects in pre...


  • Variable response of germline activating PDGFRB variants to receptor tyrosine kinase inhibitors: implications for treatment

    by Ileana Cristea, Roya Mehrasa, Titas Gladkauskas, Eyvind Rødahl, Ove Bruland, Cecilie Bredrup

    Platelet-derived growth factor receptor-beta (PDGFRβ) is a receptor tyrosine kinase that plays significant roles in cell growth, proliferation, and differentiation. Germline variants of PDGFRB can lead to several different diseases, e.g. infantile myofibromatosis, Kosaki overgrowth syndrome, Penttinen premature aging syndrome, ocular pterygium – digital keloid dysplasia, primary familial brain calcification, and others. Some variants cause the kinase to be constitutively active, even in the absence of ligand, while others lead to inactivation of signaling transduction mechanisms. Constitutive activation of PDGFRβ leads to increased cell growth, proliferation, and differentiation, which can lead to the development of tumors or other abnormal growths. The development of new therapies that target PDGFRβ is an active area of research, primarily in cancer treatment. However, these therapies have the potential to also provide effective treatment options for patients with germline variants of PDGFRB. Here, we provide a summary of recurrent activating germline variants reported in PDGFRB and examine their sensitivity to different tyrosine kinase inhibitors. We show that the respective amino acid substitutions respond differently to treatment with tyrosine kinase inhibitors that correlate with previous in vivo data. Our data may assist healthcare providers when deciding personalized treatment of patients with disorders associated with activating variants in PDGFRB.


  • Treatment Options for Alkali Burn–Induced Corneal Neovascularization: A Comparative Analysis of Two Tyrosine Kinase Inhibitors

    by Titas Gladkauskas, Ida Marie Rundgren, Ileana Cristea, Tone Bukve, Eyvind Rødahl, Cecilie Bredrup

    Purpose: To evaluate the efficacy of topical dasatinib and axitinib for treating experimentally induced corneal neovascularization (CNV) in a mouse alkali burn model, and to compare these treatments to established therapies like dexamethasone and bevacizumab. Methods: Thirty-six C57BL/6; 129 Sv mice underwent a standardized alkali burn to induce CNV in both eyes by applying a paper disc soaked in 1M NaOH to the cornea for 20 seconds. The mice were randomly assigned to one of 6 treatment groups: saline (0.9% sodium chloride), DMSO (5%), dexamethasone (0.1%), bevacizumab (0.5%), dasatinib (0.5%), or axitinib (0.5%). Treatments were applied topically 3 times daily. After 2 weeks of treatment, the mice were sacrificed. CNV assessments, including corneal neovascularization area (CNA), vessel length index (VLI), and limbus vasculature thickness, were conducted postmortem using corneal flat-mounts stained with a CD31 antibody for immunohistochemistry. Results: Dexamethasone proved the most effective in inhibiting alkali burn–induced CNA (P < 0.0001), with bevacizumab showing comparable efficacy (P < 0.001). Axitinib also effectively reduced CNA (P < 0.001) and VLI (P < 0.01). In contrast, dasatinib did not significantly reduce CNA (P = 0.74) or VLI (P = 0.98). All eyes in the dexamethasone group developed cataracts compared with 25%–41.7% in the other groups. Conclusions: Axitinib reduced CNA and VLI, although not as effectively as other established treatment modalities, whereas dasatinib did not demonstrate significant effects.


  • Open Access

    On subcellular distribution of the zinc finger 469 protein (ZNF469) and observed discrepancy in the localization of endogenous and overexpressed ZNF469

    by Anne Elisabeth Christensen Mellgren, Ileana Cristea, Thomas Stevenson, Endy Spriet, Per Morten Knappskog, Stig Ove Bøe, Harald Kranz, Sushma N. Grellscheid, Eyvind Rødahl

    The zinc finger 469 gene (ZNF469) is a single‐exon gene predicted to encode a protein of 3953 amino acids. Despite pathogenic ZNF469 variants being associated with Brittle Cornea Syndrome (BCS), relatively little is known about ZNF469 beyond its participation in regulating the expression of genes encoding extracellular matrix proteins. In this study, we examined the expression and intracellular localization of ZNF469 in different cell lines. The level of ZNF469 mRNA varied from low levels in HEK293 cells to high levels in HeLa cells and primary fibroblasts. Antibodies against ZNF469 reacted among others with a protein of approximately 400 kDa in immunoblot analysis, which was mainly present in the insoluble fraction of the cytoplasm. Immunofluorescence analysis of interphase cells showed small cytoplasmic puncta and weak nuclear staining. In dividing HeLa cells, the antibodies recognized foci that also stained for proteasomes. In transfected cells, ZNF469 was observed mainly in foci resembling nuclear speckles in interphase and at the midbody during mitosis. The nuclear foci showed overlapping staining with proteasomes. In live cell imaging, liquid‐like properties of the nuclear foci were recorded as they changed shape and position and occasionally fused with each other. During stress granule formation, cytoplasmic foci showed overlapping staining with G3BP1. Finally, in silico analysis revealed large intrinsically disordered regions with multiple low complexity domains in ZNF469. Our data indicate that ZNF469 forms aggregates possibly as biomolecular condensates when overexpressed. However, care must be taken when analyzing the intracellular distribution of ZNF469 due to the discrepancy in the localization of endogenous ZNF469 and overexpressed ZNF469 in transfected cells.

  • Open Access

    Temperature as a Key Modulator: Investigating Phosphorylation Patterns of p.Asn666 PDGFRB Variants and Their Role in Downstream Signaling

    by Titas Gladkauskas, Ileana Cristea, Roya Mehrasa, Jean-Baptiste Demoulin, Bjørn Tore Gjertsen, Ove Bruland, Eyvind Rødahl, Cecilie Bredrup

    Four different amino acid substitutions have been reported at the p.Asn666 position in platelet‐derived growth factor receptor β (PDGFRβ): p.Asn666Lys, p.Asn666Tyr, p.Asn666Ser, and p.Asn666His. All four substitutions result in strikingly different phenotypes, ranging from somatic infantile myofibromatosis in p.Asn666Lys and ocular pterygium–digital keloid dysplasia in p.Asn666Tyr to a severe form of Penttinen syndrome in p.Asn666Ser, while p.Asn666His is associated with a complex phenotype characterized by debilitating hand and foot contractures and facial coarseness. Here, we show that the p.Asn666Lys, p.Asn666Tyr, and p.Asn666His substitutions result in increased total PDGFRβ phosphorylation at 32°C compared to 37°C. All four substitutions exhibit distinct activation patterns of specific PDGFRβ tyrosine residues at both temperatures, indicating a unique activation of each variant. The temperature effect on downstream signaling is present across all substitutions, resulting in substitution‐specific downstream signaling at both 37°C and 32°C. This complex interplay of downstream signaling proteins could be important for the clinical manifestations of p.Asn666 PDGFRB variants. Furthermore, variant‐specific overactivation of tyrosine residues and downstream signaling at 32°C emphasize the importance of temperature as an environmental factor in the pathogenesis of this diverse group of disorders.


  • Open Access

    Functional characterization of all‐trans retinoic acid‐induced differentiation factor (ATRAID)

    by Roya Mehrasa, Ileana Cristea, Cecilie Bredrup, Eyvind Rødahl, Ove Bruland

    All‐trans retinoic acid‐induced differentiation (ATRAID) factor was first identified in HL60 cells. Several mRNA isoforms exist, but the respective proteins have not been fully characterized. In transfected cells expressing Myc‐Flag‐tagged ATRAID Isoform (Iso) A, B, and C, Iso C was found to be expressed at high levels, Iso A was found to be expressed at low levels due to rapid degradation, and the predicted protein expressed from Iso B was not detected. Iso C was present mainly in an N‐glycosylated form. In subcellular fractionation experiments, Iso C localized to the membranous and nuclear fractions, while immunofluorescence analysis revealed that Iso C is located close to the plasma membrane, mainly in cytoplasmic vesicles and in the Golgi area. We confirm that Iso C colocalizes to some extent with endosomal/lysosomal markers LAMP1 and LAMP2. Furthermore, we show that ATRAID co‐localizes with RAB11, a GTPase associated with recycling endosomes and implicated in regulating vesicular trafficking.


  • Open Access

    A Pellino‐2 variant is associated with constitutive NLRP3 inflammasome activation in a family with ocular pterygium–digital keloid dysplasia

    by Ileana Cristea, Hugo Abarca, Anne E. Christensen Mellgren, Milana Trubnykova, Roya Mehrasa, Dorien J. M. Peters, Gunnar Houge, Raoul C. M. Hennekam, Eyvind Rødahl, Ove Bruland, et al.

    Ocular pterygium–digital keloid dysplasia (OPDKD) is a rare hereditary disease characterized by corneal ingrowth of vascularized conjunctival tissue early in life. Later, patients develop keloids on fingers and toes but are otherwise healthy. In a recently described family with OPDKD, we report the presence of a de novo c.770C > T, p.(Thr257Ile) variant in PELI2 in the affected individual. PELI2 encodes for the E3 ubiquitin ligase Pellino‐2. In transgenic U87MG cells overexpressing Pellino‐2 with the p.(Thr257Ile) amino acid substitution, constitutive activation of the NLRP3 inflammasome was observed. However, the Thr257Ile variant did not affect Pellino‐2 intracellular localization, its binding to known interaction partners, nor its stability. Our findings indicate that constitutive autoactivation of the NLRP3 inflammasome contributes to the development of PELI2‐associated OPDKD.


  • Open Access

    Systemic Activation of the Kynurenine Pathway in Graves Disease With and Without Ophthalmopathy

    by Hans Olav Ueland, Arve Ulvik, Kristian Løvås, Anette S B Wolff, Lars Ertesvåg Breivik, Ann-Elin Meling Stokland, Eyvind Rødahl, Roy Miodini Nilsen, Eystein Husebye, Grethe Åstrøm Ueland

    Context Graves disease (GD) is one of the most common autoimmune disorders. Recent literature has shown an immune response involving several different inflammatory related proteins in these patients. Objective This work aimed to characterize the kynurenine pathway, activated during interferon-γ (IFN-γ)–mediated inflammation and cellular (T-helper type 1 [Th1] type) immunity, in GD patients with and without thyroid eye disease (TED). Methods We analyzed 34 biomarkers by mass spectrometry in serum samples from 100 patients with GD (36 with TED) and 100 matched healthy controls. The analytes included 10 metabolites and 3 indices from the kynurenine pathway, 6 microbiota-derived metabolites, 10 B-vitamers, and 5 serum proteins reflecting inflammation and kidney function. Results GD patients showed significantly elevated levels of 7 biomarkers compared with healthy controls (omega squared [ω2] > 0.06; P < .01). Of these 7, the 6 biomarkers with the strongest effect size were all components of the kynurenine pathway. Factor analysis showed that biomarkers related to cellular immunity and the Th1 responses (3-hydroxykynurenine, kynurenine, and quinolinic acid with the highest loading) were most strongly associated with GD. Further, a factor mainly reflecting acute phase response (C-reactive protein and serum amyloid A) showed weaker association with GD by factor analysis. There were no differences in biomarker levels between GD patients with and without TED. Conclusion This study supports activation of IFN-γ inflammation and Th1 cellular immunity in GD, but also a contribution of acute-phase reactants. Our finding of no difference in systemic activation of the kynurenine pathway in GD patients with and without TED implies that the local Th1 immune response in the orbit is not reflected systemically.